Barcelona, December 23, 2009.   Grifols SA, a global healthcare company specializing in biologic therapies derived from human plasma, today announced that it received approval from the US Food and Drug Administration (FDA) for use of its new sterile filling facility in Los Angeles, California for the production of life-saving albumin therapy. This approval is the culmination of a three- year project to transform the entire process of obtaining, purifying and filling albumin vials at Grifols Biologicals Inc. (GBI), the Grifols' US-based manufacturing division.

"With approval of this new method in the US, our production facilities in Barcelona and Los Angeles will adhere to precisely the same manufacturing process," explained Willie Zuñiga, President of GBI. According to Zuñiga, the new method offers a number of technical and process flow advantages over the method previously used at the LA facility. "Approval of our new albumin facility was obtained in record time and represents completion of yet another major production related advancement taking place in the US," continued Zuñiga.

Approximately two months ago, Grifols also obtained FDA approval for its new plasma fractionation facility, known as "Minifrac". With a capacity to process 700,000 liters of plasma, this brings the total fractionation capacity of the Los Angeles facilities to 2,200,000 liters per year. In addition to a number of other small-scale projects, Grifols is focused on construction of a new IVIG purification facility for Flebogamma® DIF that is planned for completion in the third quarter of 2010. Once completed, this will represent the full modernization of all Grifols' Los Angeles based production facilities.

The Flebogamma® DIF facility currently under construction in Los Angeles is the sister facility to Grifols' Flebogamma® DIF facility in Barcelona. The size complexity of the facility, which measures 10,000 square meters and includes over 50 reactors and advanced facilities for purification and filling, means that US and European regulatory approvals could take as long as two years. "We expect to start production in the first quarter of 2013," stated Dr. Javier Jorba, who is the head of Grifols' worldwide plasma product manufacturing.

In addition to the work in Los Angeles, Grifols is also constructing a second plasma analysis laboratory in the United States. The new laboratory will be located in the city of San Marcos, Texas, approximately 25 kilometers from Grifols' current central testing laboratory in Austin, Texas. The new laboratory is planned to be operational beginning in 2011.

About Grifols  
Grifols SA (Grifols) is a global healthcare company founded in 1940 in Barcelona, Spain. Today Grifols products and services are provided in more than 90 countries around the world. Grifols specializes in the production of plasma therapies to treat a variety of life-threatening diseases and conditions. Grifols operates 80 plasma donor centers throughout the US and has manufacturing facilities located in Barcelona, Spain and Los Angeles, California. Since 2006, the Company has been listed on the Spanish Stock Exchange ("Mercado Continuo") and is part of the Ibex-35. For more information about Grifols, please visit www.grifols.com.